Download Michael Nailor - Hartford Hospital

Dr. Michael Nailor’s Scholarship
Book Chapters:
Nailor MD and Sobel JD. Antibiotics for Gram-Positive Bacterial Infections: Vancomycin,
teicoplanin, Quinupristin/Dalfopristin, Oxazolidinones, Daptomycin, Telavancin, and Ceftaroline.
Medical Clinics of North America 95(4): 723-42, 2011.
Nailor MD and Sobel JD. Antibiotics for Gram-Positive Bacterial Infections: Vancomycin,
Quinupristin/Dalfopristin, Linezolid, and Daptomycin. Infectious Diseases Clinic of North America
23(4): 965-982, 2009.
Publications:
Blanchette LM, Kuti JL, Nicolau DP, and Nailor MD. Clinical Comparison of Ertapenem and
Cefepime for Treatment of Infections Caused by AmpC Beta-Lactamase Producing
Enterobacteriaceae. Scandinavian Journal of Infectious Diseases, 46:803-8, 2014.
Martin ST, Cardwell SM, Nailor MD, and Gabardi S. Hepatitis B reactivation and rituximab: a new
boxed warning and considerations for solid organ transplantation. American Journal of
Transplantation, 14:788-96, 2014.
Macedo KA and Nailor MD. Focus on tapentadol: role in the treatment of neuropathic pain.
Formulary, 48:378-403, 2013.
Raman K, Nailor MD, Nicolau DP, Aslanzadeh J, Nadeau M, Kuti JL. Early Antibiotic
Discontinuation is Not Associated with Increased Mortality in Patients with Clinically Suspected
Ventilator Associated Pneumonia (VAP) and Negative Quantitative Bronchoscopy Cultures.
Critical Care Medicine, 41: 1656-63, 2013.
Wilde AM, Nailor MD, Nicolau DP, and Kuti JL. Decreased Compliance of a Ventilator-Associated
Pneumonia (VAP) Computerized Clinical Pathway Results in Inappropriate Antibiotic Utilization:
Implications for Continuing Education and Prospective Feedback. Pharmacotherapy, 32: 755-63,
2012.
Delgado A and Nailor MD. Initial Posaconazole Prophylactic Dosing and Serum Levels in Heart
Transplant Patients. Connecticut Medicine, 76: 413-5, 2012.
Boyd N and Nailor MD. Insights from the Society of Infectious Diseases Pharmacists:
combination antibiotic therapy for treatment of serious Gram-negative infections.
Pharmacotherapy, 31: 1073-84, 2011.
Zimmerman LH, Tyburski JG, Glowniak J, Singla R, Lavery T, Nailor MD, Stassinopoulus J, Hong
K, Barshikar S, Dolman HS, Baylor AE, Wilson RF. Impact of evaluating antibiotic concentrations
in abdominal abscesses percutaneously drain. The American Journal of Surgery, 201: 348-352,
2011.
Bulik CC, Sobel JD, and Nailor MD. Susceptibility profile of vaginal isolates of Candida albicans
prior to and following fluconazole introduction – impact of two decades. Mycoses, 54(1): 34-8,
2011.
Boyd N and Nailor MD. Combination antibiotic therapy for treatment of serious Gram-negative
infections. Society of Infectious Diseases Pharmacists Newsletter, 20(3): 19-28, 2010
Wilde AM and Nailor MD. Use of Monte Carlo simulations in predicting antimicrobial response
with continuous and extended infusions of beta-lactam antibiotics. Connecticut Medicine, 74 (4):
223-8, 2010.
Nailor MD and Chandrasekar PH. Treatment of breakthrough fungal infections: is there one best
drug strategy? Current Fungal Infections Reports, 3(4): 229-235, 2009.
Nailor MD and Chandrasekar PH. Antifungal Drugs: Predicting Clinical Efficacy with
Pharmacodyanmics. Expert Review of Clinical Pharmacology, 2(4): 373-379, 2009.
Dickey LJ, Nailor MD, and Sobel JD. Guidelines for the treatment of bacterial vaginosis: focus on
tinidazole. Therapeutics and Clinical Risk Management, 5: 485-489, 2009.
Revankar SG, Nailor MD, and Sobel JD. Use of Terbinafine in Rare and Refractory Mycoses.
Future Microbiology, 3(1):9-17, 2008.
Nailor MD and Sobel JD. Tinidazole for the Treatment of Vaginal Infections. Expert Opinion of
Investigational Drugs, 16(5): 743-751, 2007.
Nailor MD and Sobel JD. Tinidazole for Bacterial Vaginosis. Expert Review of Anti-Infective
Therapy, 5(3): 343-348, 2007.
Nailor MD and Sobel JD. Progress in Anti-fungal Therapy: Echinocandins versus Azoles. Drug
Discovery Today: Therapeutic Strategies, Summer 2006: 221-226.
Abstracts:
Cardwell SM, Crandon JL, Nicolau DP, McClure MH, and Nailor MD. Identification of exposures
associated with resistant pathogens in urinary tract infections. ICAAC September 2014.
Cardwell SM, Crandon JL, Nicolau DP, McClure MH, and Nailor MD. Predictors of financial
outcomes in the management of urinary tract infections. ICAAC September 2014.
Strawbridge S and Nailor MD. Safety of high dose doripenem in patients with cystic fibrosis.
ICAAC September 2014.
Simonds LM, Coleman CI, and Nailor MD. Implications of culture negative nursing home-acquired
pneumonia in antimicrobial de-escalation. ASHP Midyear December 2013.
Hagstrom KL, Gannon D, Nailor MD, Hobbs LC, Lindberg MC, and Sobieraj DM. Association of
potentially inappropriate medication use in the elderly and hospital-related outcomes. ASHP
Midyear December 2013.
Strawbridge SA and Nailor MD. Safety profile of high dose doripenem in patients with cystic
fibrosis. ASHP Midyear December 2013.
Dollard EW, Easow J, Chan CJ, Tran NN, Gannon R, and Nailor MD. Naloxone use after
implementing a comprehensive verification process by pharmacists for adults receiving high dose
opioids. ASHP Midyear December 2013.
Blanchette LM, Kuti JL, Nicolau DP, Nailor MD. Comparative clinical and economic outcomes of
ertapenem treated patients with infections caused by AmpC beta-lactamase producing
enterobacteriaceae. ICAAC September 2013.
Blanchette LM, Butler K, Cheema F, Pope S, Nailor MD. Diagnostic predictive value of the
Clinical Pulmonary Infection Score (CPIS) versus the Hartford Hospital Two + Two system for
identifying patients with suspected Ventilator Associated Pneumonia (VAP). ASHP Midyear
December 2012.
Zlotnik K, Jacknin G, Nailor MD. Adherence to ADA guidelines recommendations for electrolyte
monitoring in patients with DKA and HHS in Hartford Hospital emergency department. ASHP
Midyear December 2012.
Nolan W, Jacknin G, Nailor MD. Evaluation of educational efforts to healthcare staff to decrease
time to N-acetylcysteine administration in suspected acetaminophen overdose. ASHP Midyear
December 2012.
Semancik L, Tessier N, Nailor MD. Impact of discharge counseling about cardiology medications
on Hospital Consumer Assessment of Healthcare Providers and Systems scores. ASHP Midyear
December 2012
Zmarlicka M, Jahn H, Hagestrom K, Zhu Y, Tandon M, Hobbs L, Nailor MD. Venous
thromboembolism prophylaxis usage in surgical patients acquiring VTE. ASHP Midyear
December 2012.
Lo C, Lourie I, Tuminska A, Urban R, Tishler D, Papasavas P, Gannon R, Nailor MD. Outcomes
of intravenous acetaminophen use in patients with laparoscopic gastric banding. ASHP Midyear
December 2012.
Raman K, Nailor MD, Nicolau DP, Aslanzdeh J, Kuti JL. Antibiotic discontinuation is not
associated with mortality in suspected ventilator associated pneumonia (VAP) and negative
quantitative bronchoscopy cultures. ICAAC September 2012. Accepted for Platform Presentation.
Kunac A, Nailor MD, Wills D, Kelliher K, Modeste K, Brautigam R, Butler K. The VAP bundle is
not enough: mitigating the risk of frequent intra-hospital transports from the ICU. New England
Surgical Society September 2012. Accepted for Platform Presentation.
Raman K*, Nailor MD, Nicolau DP, Aslanzdeh J, Kuti JL. Antibiotic discontinuation is not
associated with mortality in suspected ventilator associated pneumonia (VAP) and negative
quantitative bronchoscopy cultures. Connecticut Infectious Diseases Society Conference May
2012. *Winner of Young Investigator of the Year Award*
Modeste KA, Staff I, Kelliher KM, Nailor MD, Brautigam R, and Butler K. Is BMI a risk factor for
VAP in the critically ill surgical patient? Society of Black Academic Surgeons April 2012.
Kelliher KM, Nailor MD, Staff I, Brautigam R, and Butler K. Intra-hospital transport increases the
risk of VAP in critically ill surgical patients. SCCM January 2012.
Nailor MD, Wilde AM, Schlesselman LS. Impact of a pharmacy resident led lecture series on
pharmacy student clinical knowledge. ASHP Midyear December 2011.
Krawczynski MA, Ross J, Sobieraj DM, Coleman CI, and Nailor MD. Evaluating low health
literacy as a predictor for HIV-1 resistance mutations. ASHP Midyear December 2011.
Nguyen JT and Nailor MD. Analysis of a new pharmacist initiated, nurse implemented
vancomycin trough level ordering process. ASHP Midyear December 2011.
Raman K, Delgado J, and Nailor MD. Use of a disease-specific antibiogram to improve therapy
for long-term care facility-acquired tract infections. ASHP Midyear December 2011.
Wilde AM, Nailor MD, Nicolau DP, and Kuti JL. Decreased compliance of a ventilator associated
pneumonia (VAP) clinical pathway results in inappropriate antibiotic utilization and increasing
mortality. IDSA October 2011.
Flatley, EA, Wilde AM, and Nailor MD. Removal of Saccharomyces boulardii from a hospital
formulary and the impact on Clostridium difficile-associated diarrhea. ICAAC September 2011.
Wilde AM*, Nailor MD, Nicolau DP, and Kuti JL. Validation of a ventilator associated pneumonia
th
(VAP) clinical pathway using quantitative brochoalveolar lavage for diagnosis. 29 Connecticut
Infectious Diseases Society Conference May 2011. *Winner of Young Investigator of the Year
Award*
Delgado AM and Nailor MD. Posaconazole serum drug concentration in patients with heart
transplants. ASHP Midyear December 2010.
Wilde AM and Nailor MD. Oral vancomycin for the prevention of Clostridium difficile infection.
ASHP Midyear December 2010.
Wilde AM and Nailor MD. Impact of vancomycin dosing maximums in high trough targeting
therapy. ASHP Midyear December 2009.
Dickey LJ, Raygada, J, Kosmidis C, Seo SM, Nailor MD, and Kaatz GW. Chlorhexidine oral
decontamination and multidrug efflux pump activity in Lac+ bacteria. ICAAC September 2009.
Dickey LG, Nailor MD, Wood T, and Browning LA. Evaluating the use of the clinical pulmonary
infection score in patients admitted to the medical intensive care unit with pneumonia. MAD-ID
May 2009
Nailor MD, Zhao JJ, and Salimnia H. Daptomycin for Methicillin Resistant Staphylococcus aureus
bacteremia with Elevated Vancomycin Minimum Inhibitor Concentrations. ICAAC/IDSA October
2008.
Fairfax MR, Nailor MD, Painter T, Lerch RJ, and Salimnia H. Vancomycin and Daptomycin
Susceptibility Testing of Staphylococcus aureus in a Clinical Laboratory. ICAAC/IDSA October
2008.
Narreddy S, Quezada N, Jain R, Salimnia H, Nailor MD, Chamber R, Painter T, Thomas R, and
Chandrasekar PH. Clinical Impact of the Staphylococcus aureus PNA FISH Test for Early
Differentiation between S. aureus and non-aureus Staphylococcal Bacteremia. ICAAC/IDSA
October 2008.
Bulik CC, Sobel JD, and Nailor MD. Susceptibility Profile of C. albicans from Vaginal Isoaltes
Prior to and Following Fluconazole Introduction. ACCP October 2008
Zhao JJ, Levine DP, Brown PD., and Nailor MD. Evaluation of Surgical Therapy in the Treatment
of Infective Endocarditis. IDSA October 2007
Zhao JJ and Nailor MD. Tigecycyline Utilization Review at Detroit Receiving Hospital. ASHP
Midyear Meeting. December 2006.
Hall LM, Farber MS, and Nailor MD. Focused Study of Vancomycin Utilization at 72 Hours in a
University Hospital. ASHP Midyear Meeting. December 2005. RP 313
Nailor MD, Carver PL., DePestel DD, and Kauffman CA. Epidemiology of Scedosporium Species:
Colonization or Infection? IDSA October 2004.
Carver PL, Nailor MD, DePestel DD, and Kraft MD. Risk factors for the development of linezolid
resistant Enterococci. International Congress on Clinical Pharmacy April 2004.
Nailor MD, DePestel DD, Kraft MD, and Carver PL. Risk factors for the development of linezolid
resistant Enterococci. UHC Annual Meeting. December 2003.
Certificate Program Development
American Society of Consultant Pharmacists Certified Geriatric Pharmacist Course Review: 2.5
hours of CE, Pneumonia and Upper Respiratory Tract Infections 2014
American Society of Consultant Pharmacists Certified Geriatric Pharmacist Course Review: 2.5
hours of CE, Clostridium difficile Infections 2014
The Society of Infectious Diseases Pharmacists: Overview of Antibiotic Stewardship, A Certificate
Program for Pharmacists 39 hours of CE, one of many authors. 2012, updated 2014.